New hope for advanced lung cancer patients in global drug trial
Disease control
Not yet recruiting
This global study is testing whether adding an experimental drug called EIK1001 to standard immunotherapy and chemotherapy can better control advanced lung cancer. It will involve 750 adults with stage 4 non-small cell lung cancer who have not yet received treatment for their adv…
Phase: PHASE2, PHASE3 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC